MTOR and lymphangioma: Another study showed that rapamycin (sirolimus), a mammalian target of rapamycin (mTOR) inhibitor, can inhibit the excessive growth of lymphatic vessels in mouse models of LM driven by mutations of the PIK3CA gene (4).